In the Invited Commentary titled “Prognostication of Uveal Melanoma: A Work in Progress,” published online April 28, 2016,1 Dr Singh failed to declare several conflicts of interest relevant to the subject matter. In January 2016, he participated in a uveal melanoma meeting hosted by Castle Biosciences as a member of the Castle Biosciences Advisory Board, for which he received compensation. He also received compensation for his role as an advisory board member of Aura Biosciences and Iconic Therapeutics related to investigations of novel therapies for primary uveal melanoma. He also has a pending patent application for a risk calculator of vision loss following brachytherapy. This article was corrected online.